All cancer tissue phenotypes are initiated by deregulated signalling mechanisms in cancer cells. Signalling mechanisms are also the largest target mechanism entity for targeted cancer therapies. Recent data also strongly indicate that cancer therapy resistance is initiated by non-genetic signaling rewiring via post-translational regulation of proteins involved in signalling networks and transcriptional gene regulation.

However, regardless of decades of research, our global understanding of how cancer cell signalling circuits are controlled, and how they determine cancer progression and therapy resistance, is still far from complete. This conference will focus on basic mechanisms controlling cancer cell signalling circuits at the transcriptome, proteome and phosphoproteome levels as well as emerging concepts in cancer cell signalling.